March 2012
Volume 53, Issue 14
ARVO Annual Meeting Abstract  |   March 2012
Ozurdex: A new therapeutic option in uveitis - Clinical outcome from two German uveitis centers
Author Affiliations & Notes
  • Uwe Pleyer
    Ophthalmology, University Charite Berlin, Berlin, Germany
  • Matthias Klamann
    Ophthalmology, University Charite Berlin, Berlin, Germany
  • Sibylle Winterhalter
    Ophthalmology, University Charite Berlin, Berlin, Germany
  • Stephan R. Thurau
    Dept of Ophthalmology, Ludwig-Maximilians-University, Munich, Germany
  • Footnotes
    Commercial Relationships  Uwe Pleyer, Abbott, Alcon, Allergan, Amgen, Bausch und (C); Matthias Klamann, None; Sibylle Winterhalter, None; Stephan R. Thurau, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 2249. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Uwe Pleyer, Matthias Klamann, Sibylle Winterhalter, Stephan R. Thurau; Ozurdex: A new therapeutic option in uveitis - Clinical outcome from two German uveitis centers. Invest. Ophthalmol. Vis. Sci. 2012;53(14):2249.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To report the experience of two German uveitis centers with a dexamethasone 0.7 mg sustained-release intravitreal implant (Ozurdex TM; Allergan, Inc, Irvine, CA) in noninfectious posterior uveitis.

Methods: : The study included 58 eyes with noninfectious uveitis receiving one or more intravitreal injections of a commercially available dexamethasone implant (s), Ozurdex TM. Main outcome measures: Complete ophthalmic examination including signs of inflammatory activity, visual acuity, optical coherence tomography and adverse effects and tolerability of the implant were assessed.

Results: : Fifty eight eyes of 48 consecutive patients treated with a total of 63 dexamethasone 0.7 mg sustained-release intravitreal implants for posterior noninfectious uveitis were included. Patients presented with unilateral (n=13) or bilateral posterior/intermediate uveitis (n=45). All eyes showed clinical and morphological evidence of decreased inflammation following implant placement. Maximum clearance of vitreous haze could be achieved within 4 weeks in 82% of all treated eyes (p<0.01), whereas significant reduction (p<0.05) of central retinal thickness was reached at 3 months. Within the mean follow-up of 8.8 months increased IOP (+ 5mmHg) was observed in 43 % of all eyes and reached 35mmHg or above in 12% of all patients. All events of ocular hypertension could be controlled with conservative treatment. No serious ocular or systemic adverse events were noted during the follow-up period.

Conclusions: : In patients with noninfectious posterior/intermediate uveitis, the sustained-release dexamethasone 0.7 mg intravitreal implant is an effective treatment option for controlling intraocular inflammation.

Keywords: uveitis-clinical/animal model • macula/fovea • corticosteroids 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.